红花逍遥丸治疗围绝经期综合征的随机对照试验方案
主要结局为改良Kupperman指数,次要结局包括潮热评分、绝经期生活质量量表及抑郁焦虑量表,并检测性激素、单胺类神经递质、血管舒缩因子及PI3K/Akt表达,以评估疗效、安全性和可能机制。
要点
- 主要结局为改良Kupperman指数,在基线及第4、8、12、16周测量。
- 次要结局包括潮热评分、MENQOL、HAMD/HAMA及血清性激素等机制指标。
核心结论
- 该试验旨在评估红花逍遥丸治疗围绝经期综合征的疗效与安全性,并探索其可能机制。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要结局为改良Kupperman指数,于基线及随机后第4、8、12、16周测量。
- 潮热评分测量时间点与Kupperman指数相同;MENQOL、HAMD/HAMA于基线及随机后第12、16周测量。
- 血清性激素、单胺类神经递质、血管舒缩因子及PI3K/Akt表达于基线及随机后第12周测量。
临床怎么用
- 该方案为红花逍遥丸用于围绝经期综合征的疗效和安全性评价提供随机对照试验设计框架。
局限性
- 原文为研究方案,尚未提供疗效和安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Peri-menopausal syndrome (PMPS) has a high incidence rate and seriously affects the physical and mental health of women. Honghua Xiaoyao Pill (HHXYP) is a Chinese patent medicine, which has been reported to be used to treat PMPS. However, there is still a lack of randomized clinical trial to evaluate the efficacy and safety of HHXYP on life quality, mood and vasomotor symptoms for PMPS women. This study aims to investigate whether HHXYP is effective and safe in treating PMPS and the possible mechanism. Methods: A multicenter, randomized, controlled clinical trial will be conducted in China to evaluate the efficacy and safety of HHXYP. Sixty women with peri-menopausal syndrome will be recruited at three centers and randomly in a 1:1 ratio to a treatment group using HHXYP (HHXYP group) and a control group using oryzanol (OC group). Participants will be treated with HHXYP or oryzanol for 12 weeks and followed up for 4 weeks. The primary outcome is the modified Kupperman Index (KI), which will be measured at baseline and 4, 8, 12, 16 weeks after randomization. The secondary outcomes include Hot flash scale (HFs), Menopause-Specific Quality of Life Scale (MENQOL) and Hamilton Depression/Anxiety Scale (HAMD/HAMA). The HFs are measured at the same point as the KI, other secondary outcomes are measured at baseline and 12, 16 weeks after randomization. The other outcomes are the levels of serum sex hormone, monoamine neurotransmitter, vascular vasomotor factor and the expression of phosphatidylinositol 3-active enzyme (PI3K)/protein activator enzyme B (Akt), which will be measured at baseline and 12 weeks after randomization. Adverse events will also be reported. Discussion: HHXYP is a potential alternative Chinese patent medicine for PMPS. This trial will provide evidence for HHXYP on improving the quality of life, mood and vasomotor symptoms, and sex hormone levels of PMPS patients.
引用
- Wu X, Zhou L, Dong H, et al. Efficacy, safety and mechanism of Honghua Xiaoyao Pill in the treatment of peri-menopausal syndrome: A study protocol for a randomized controlled trial. Front Pharmacol. 2022. PMID: 36569324. doi:10.3389/fphar.2022.1001228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。